GlassScriptPhysician profile
Michael H Pourfar
NPI 1730169905
$23,481.75
in general payments reported to CMS, 2019-2025
15 companies · $5,580 in 2025
The $5,580 reported for 2025 was more than what 86% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $13K · 2020: $365 · 2023: $682 · 2024: $4,305 · 2025: $5,580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,410 · Consulting Fee: $3,063 · Food and Beverage: $3,021 · Travel and Lodging: $73.19.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,410.00 |
| Consulting Fee | $3,062.50 |
| Food and Beverage | $3,021.36 |
| Travel and Lodging | $73.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $15,029.42 | 2019-2025 | Infinity |
| Boston Scientific Corporation | $3,808.92 | 2019-2025 | Vercise, General - Dbs |
| Mdd US Operations, LLC | $2,726.22 | 2019 | |
| Medtronic, INC. | $412.33 | 2023-2025 | Percept PC Brainsense |
| Abbvie INC. | $335.47 | 2020-2025 | |
| Insightec,INC | $238.10 | 2024-2025 | Exablate |
| Medtronic USA, INC. | $203.78 | 2019 | |
| Acadia Pharmaceuticals INC | $193.14 | 2019-2024 | Nuplazid |
| Adamas Pharmaceuticals, INC. | $135.72 | 2019-2020 | |
| Amneal Pharmaceuticals LLC | $131.44 | 2019-2025 | Crexont |
| Acorda Therapeutics, INC | $117.55 | 2019 | |
| Vertical Pharmaceuticals, LLC | $87.12 | 2019 | |
| Neurocrine Biosciences, INC. | $35.82 | 2020 | |
| Kyowa Kirin, INC. | $26.72 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Pourfar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.